US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Innate Pharma

1.99

0.0000

Volume:- -

Turnover:- -

Market Cap:183.39M

PE:-3.15

High:1.99

Open:1.99

Low:1.99

Close:1.99

52wk High:2.90

52wk Low:1.31

Shares:92.16M

Float Shares:34.42M

Volume Ratio:0.01

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.6319

EPS(LYR):-0.6319

ROE:-271.37%

ROA:-25.92%

PB:30.62

PE(LYR):-3.15

Loading ...

Overview Company News Filings

Innate Pharma Releases Share and Voting Rights Update as of November 27, 2025

Innate Pharma’s Q3 2025 Update: FDA Clears Phase 3 Trial for Lacutamab

ADRs Advance; Innate Pharma S.A. Climbs 30%

Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy

MT Newswires Live

Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright

Innate Pharma Price Target Maintained With a $8.00/Share by BTIG

Innate Pharma’s IPH4502: A Promising Step in Cancer Treatment

Innate Pharma’s IPH6501 Trial: A Potential Game-Changer in Non-Hodgkin Lymphoma Treatment

Innate Pharma initiated with a Buy at Lucid Capital

Innate Pharma management to meet with BTIG

Innate Pharma Shares Fall After Downgrades by Leerink, HC Wainwright.

MT Newswires Live

HC Wainwright Downgrades Innate Pharma to Neutral From Buy

MT Newswires Live

Innate Pharma Cut to Neutral From Buy by HC Wainwright & Co.

Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright

Innate Pharma Reports First Half 2025 Earnings

Innate Pharma’s Strategic Shift in Earnings Call

Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating

Innate Pharma downgraded to Market Perform from Outperform at Leerink

Innate Pharma Reports H1 2025 Progress and Strategic Focus

Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/IPHYF/news"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IPHYF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","market":"US","secType":"STK","nameCN":"Innate Pharma","latestPrice":1.99,"timestamp":1764968400000,"preClose":1.99,"halted":0,"volume":0,"delay":15,"floatShares":34422236,"shares":92157798,"eps":-0.63191,"marketStatus":"Market Closed","change":0,"latestTime":"12-05 16:00:00 EST Delay","open":1.99,"high":1.99,"low":1.99,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.63191,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1765184400000},"marketStatusCode":7,"adr":0,"adrRate":0,"exchange":"PINK LIMITED","adjPreClose":1.99,"volumeRatio":0.007304601807034044},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IPHYF\",,,,,undefined,":{"symbol":"IPHYF","floatShares":34422236,"roa":"-25.92%","roe":"-271.37%","lyrEps":-0.63191,"volumeRatio":0.007304601807034044,"shares":92157798,"dividePrice":0,"high":1.99,"amplitude":0,"preClose":1.99,"low":1.99,"week52Low":1.31,"pbRate":"30.62","psRate":"12.46","week52High":2.9,"institutionHeld":0,"latestPrice":1.99,"eps":-0.63191,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.63191,"open":1.99,"prevYearClose":2.9,"prevWeekClose":1.995,"prevMonthClose":1.995,"prevQuarterClose":2,"fiveDayClose":1.995,"twentyDayClose":2,"sixtyDayClose":1.62},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IPHYF\",params:#limit:5,,,undefined,":[{"date":"2024-05-14","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1715673600000,"name":null,"time":"Pre-Market","dateTimestamp":1715659200000,"actualEps":null},{"market":"US","date":"2022-11-07","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"Pre-Market","type":"earning","dateTimestamp":1667797200000,"reportTimeType":"pre","actualEps":null},{"market":"US","date":"2022-09-15","symbol":"IPHYF","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"","type":"earning","dateTimestamp":1663214400000,"reportTimeType":"","actualEps":null},{"date":"2022-03-24","symbol":"IPHYF","type":"earning","reportTimeType":"pre","market":"US","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1648108800000,"name":null,"time":"Pre-Market","dateTimestamp":1648094400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IPHYF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IPHYF\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.2,"buy":0.6,"hold":0.2,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.6,"analysts":5,"updateTime":1761714000000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IPHYF\",pageSize:20,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2586733998","title":"Innate Pharma Releases Share and Voting Rights Update as of November 27, 2025","url":"https://stock-news.laohu8.com/highlight/detail?id=2586733998","media":"TIPRANKS","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2586733998?lang=en_us&edition=fundamental","pubTime":"2025-11-28 22:27","pubTimestamp":1764340076,"startTime":"0","endTime":"0","summary":"Innate Pharma SA ( ($FR:IPH) ) has provided an update. On November 28, 2025, Innate Pharma S.A. released its total number of shares and voting righ...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-releases-share-and-voting-rights-update-as-of-november-27-2025?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-releases-share-and-voting-rights-update-as-of-november-27-2025?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2583561298","title":"Innate Pharma’s Q3 2025 Update: FDA Clears Phase 3 Trial for Lacutamab","url":"https://stock-news.laohu8.com/highlight/detail?id=2583561298","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2583561298?lang=en_us&edition=fundamental","pubTime":"2025-11-13 19:38","pubTimestamp":1763033924,"startTime":"0","endTime":"0","summary":"Innate Pharma SA ( ($FR:IPH) ) has shared an update. Innate Pharma S.A. reported its third-quarter 2025 business update and financial results, high...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-q3-2025-update-fda-clears-phase-3-trial-for-lacutamab?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-q3-2025-update-fda-clears-phase-3-trial-for-lacutamab?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2582383896","title":"ADRs Advance; Innate Pharma S.A. Climbs 30%","url":"https://stock-news.laohu8.com/highlight/detail?id=2582383896","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582383896?lang=en_us&edition=fundamental","pubTime":"2025-11-11 05:30","pubTimestamp":1762810200,"startTime":"0","endTime":"0","summary":"This article was automatically generated by Dow Jones using technology from Automated Insights.International stocks trading in New York closed higher on Monday, as the S&P/BNY Mellon index of American depositary receipts increased 1.6% to 231.45.The European index increased 1.4% to 202.63. The Asian index added 1.8% to 311.52. The Latin American index gained 0.8% to 235.78, while the emerging-markets index rose 2.1% to 525.67.France's Innate Pharma S.A. was the biggest leader during the session, rocketing 30% to $2.30, and Singapore-based Trident Digital Tech Holdings Ltd. jumped 18% to 70 cents. XPeng Inc., which is based in China, rounded out the top three leaders on Monday, with shares jumping 16% to $26.04.Zepp Health Corp., based in China, posted the largest decline, plunging 18% to $22.40, followed by shares of United Kingdom's Barinthus Biotherapeutics PLC, which tumbled 18% to 88 cents. Shares of United Kingdom-based Wing Yip Food Holdings Group Ltd. plunged 10% to 91 cents.","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","IPHYF"],"gpt_icon":0},{"id":"2582443821","title":"Innate Pharma Receives US FDA Clearance to Begin Phase 3 Trial of Potential Skin Cancer Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=2582443821","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2582443821?lang=en_us&edition=fundamental","pubTime":"2025-11-10 17:45","pubTimestamp":1762767958,"startTime":"0","endTime":"0","summary":"Innate Pharma  said Monday that the US Food and Drug Administration completed a review of its confirmatory phase 3 protocol for lacutamab as a possible treatment for cutaneous T-cell lymphomas, clearing the trial to move forward.The phase 3 trial is designed to show the efficacy of lacutamab in patients with Sezary syndrome and Mycosis fungoides who have failed at least one prior line of therapy, the company said.The trial, set to begin in H1 2026, will include separate cohorts for patients with Sezary syndrome and mycosis fungoides, with progression-free survival as the primary endpoint, the company said.The company said the FDA provided \"encouraging initial feedback\" on its proposed regulatory pathway, which could potentially include accelerated approval for the Sezary syndrome indication once the Phase 3 trial is underway.Sezary syndrome is a rare cancer impacting the skin and blood, while mycosis fungoides is the most common type of skin cancer.Shares of the company were up 16% in ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHA","BK4139","IPHYF"],"gpt_icon":0},{"id":"2579976581","title":"Innate Pharma upgraded to Buy from Neutral at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2579976581","media":"TIPRANKS","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579976581?lang=en_us&edition=fundamental","pubTime":"2025-10-29 18:10","pubTimestamp":1761732627,"startTime":"0","endTime":"0","summary":"H.C. Wainwright upgraded Innate Pharma (IPHA) to Buy from Neutral with a $5 price target The company announced its intention to file an application...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innate-pharma-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innate-pharma-upgraded-to-buy-from-neutral-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2579697389","title":"Innate Pharma Price Target Maintained With a $8.00/Share by BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2579697389","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2579697389?lang=en_us&edition=fundamental","pubTime":"2025-10-29 17:44","pubTimestamp":1761731040,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IPHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  October 29, 2025 05:44 ET (09:44 GMT)","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF"],"gpt_icon":0},{"id":"2578162085","title":"Innate Pharma’s IPH4502: A Promising Step in Cancer Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578162085","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578162085?lang=en_us&edition=fundamental","pubTime":"2025-10-28 03:15","pubTimestamp":1761592528,"startTime":"0","endTime":"0","summary":"Innate Pharma S.A. (($IPHYF)) announced an update on their ongoing clinical study. Innate Pharma S.A. is conducting a Phase 1 clinical study titled...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-iph4502-a-promising-step-in-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-iph4502-a-promising-step-in-cancer-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2578621763","title":"Innate Pharma’s IPH6501 Trial: A Potential Game-Changer in Non-Hodgkin Lymphoma Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2578621763","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2578621763?lang=en_us&edition=fundamental","pubTime":"2025-10-28 01:38","pubTimestamp":1761586710,"startTime":"0","endTime":"0","summary":"Innate Pharma S.A. (($IPHYF)) announced an update on their ongoing clinical study. Study Overview: Innate Pharma S.A. is conducting a Phase 1/2 cli...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-iph6501-trial-a-potential-game-changer-in-non-hodgkin-lymphoma-treatment?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-iph6501-trial-a-potential-game-changer-in-non-hodgkin-lymphoma-treatment?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2577741305","title":"Innate Pharma initiated with a Buy at Lucid Capital","url":"https://stock-news.laohu8.com/highlight/detail?id=2577741305","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2577741305?lang=en_us&edition=fundamental","pubTime":"2025-10-23 19:20","pubTimestamp":1761218413,"startTime":"0","endTime":"0","summary":"Lucid Capital initiated coverage of Innate Pharma (IPHA) with a Buy rating and $8 price target Innate is a clinical-stage biotechnology company foc...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innate-pharma-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innate-pharma-initiated-with-a-buy-at-lucid-capital-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BK4551","BK4596","IPHYF","LCID","IPHA","BK4555","BK4099"],"gpt_icon":0},{"id":"2572444541","title":"Innate Pharma management to meet with BTIG","url":"https://stock-news.laohu8.com/highlight/detail?id=2572444541","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2572444541?lang=en_us&edition=fundamental","pubTime":"2025-10-03 00:45","pubTimestamp":1759423509,"startTime":"0","endTime":"0","summary":"Meeting to be held in New York on October 9-10 hosted by BTIG. Published first on TheFly – the ultimate source for real-time, market-moving breakin...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innate-pharma-management-to-meet-with-btig-thefly-2?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innate-pharma-management-to-meet-with-btig-thefly-2?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF","BK4139"],"gpt_icon":0},{"id":"2568040018","title":"Innate Pharma Shares Fall After Downgrades by Leerink, HC Wainwright.","url":"https://stock-news.laohu8.com/highlight/detail?id=2568040018","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568040018?lang=en_us&edition=fundamental","pubTime":"2025-09-19 03:19","pubTimestamp":1758223169,"startTime":"0","endTime":"0","summary":"Innate Pharma  shares fell 4.9% in recent Thursday trading after downgrades by Leerink and HC Wainwright.Leerink downgraded the stock to market perform from outperform and adjusted its price target to $2 from $10. HC Wainwright lowered its rating to neutral from buy.Innate Pharma's intraday volume topped 12,300 shares, versus the daily average of 11,987.Price: 1.95, Change: -0.10, Percent Change: -4.88","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568718264","title":"HC Wainwright Downgrades Innate Pharma to Neutral From Buy","url":"https://stock-news.laohu8.com/highlight/detail?id=2568718264","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568718264?lang=en_us&edition=fundamental","pubTime":"2025-09-18 19:22","pubTimestamp":1758194543,"startTime":"0","endTime":"0","summary":"HC Wainwright Downgrades Innate Pharma to Neutral From Buy","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568763564","title":"Innate Pharma Cut to Neutral From Buy by HC Wainwright & Co.","url":"https://stock-news.laohu8.com/highlight/detail?id=2568763564","media":"Dow Jones","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568763564?lang=en_us&edition=fundamental","pubTime":"2025-09-18 18:33","pubTimestamp":1758191580,"startTime":"0","endTime":"0","summary":"Ratings actions from Benzinga: https://www.benzinga.com/quote/IPHA/analyst-ratings \n\n\n \n\n\n  (END) Dow Jones Newswires\n\n\n  September 18, 2025 06:33 ET (10:33 GMT)","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF"],"gpt_icon":0},{"id":"2568475930","title":"Innate Pharma downgraded to Neutral from Buy at H.C. Wainwright","url":"https://stock-news.laohu8.com/highlight/detail?id=2568475930","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568475930?lang=en_us&edition=fundamental","pubTime":"2025-09-18 18:05","pubTimestamp":1758189936,"startTime":"0","endTime":"0","summary":"H.C. Wainwright downgraded Innate Pharma (IPHA) to Neutral from Buy without a price target The company is prioritizing three assets, IP4502, lacuta...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innate-pharma-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innate-pharma-downgraded-to-neutral-from-buy-at-h-c-wainwright-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568044054","title":"Innate Pharma Reports First Half 2025 Earnings","url":"https://stock-news.laohu8.com/highlight/detail?id=2568044054","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568044054?lang=en_us&edition=fundamental","pubTime":"2025-09-18 11:54","pubTimestamp":1758167662,"startTime":"0","endTime":"0","summary":"Innate Pharma S.A. ( ($IPHYF) ) has released its Q2 earnings. Here is a breakdown of the information Innate Pharma S.A. presented to its investors....","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-reports-first-half-2025-earnings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-reports-first-half-2025-earnings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568445180","title":"Innate Pharma’s Strategic Shift in Earnings Call","url":"https://stock-news.laohu8.com/highlight/detail?id=2568445180","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568445180?lang=en_us&edition=fundamental","pubTime":"2025-09-18 08:07","pubTimestamp":1758154033,"startTime":"0","endTime":"0","summary":"Innate Pharma S.A. (($FR:IPH)) has held its Q2 earnings call. Read on for the main highlights of the call. In the recent earnings call, Innate Phar...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-strategic-shift-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharmas-strategic-shift-in-earnings-call?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568448040","title":"Innate Pharma’s Strategic Shift and Financial Challenges Lead to Hold Rating","url":"https://stock-news.laohu8.com/highlight/detail?id=2568448040","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568448040?lang=en_us&edition=fundamental","pubTime":"2025-09-18 06:45","pubTimestamp":1758149113,"startTime":"0","endTime":"0","summary":"Leerink Partners analyst Daina Graybosch downgraded the rating on Innate Pharma to a Hold today, setting a price target of $2.00. Daina Graybosch’s...","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/ratings/innate-pharmas-strategic-shift-and-financial-challenges-lead-to-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/ratings/innate-pharmas-strategic-shift-and-financial-challenges-lead-to-hold-rating-ratings?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568444874","title":"Innate Pharma downgraded to Market Perform from Outperform at Leerink","url":"https://stock-news.laohu8.com/highlight/detail?id=2568444874","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568444874?lang=en_us&edition=fundamental","pubTime":"2025-09-18 06:40","pubTimestamp":1758148814,"startTime":"0","endTime":"0","summary":"Leerink downgraded Innate Pharma (IPHA) to Market Perform from Outperform with a price target of $2, down from $10. The company relegating their pr...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/innate-pharma-downgraded-to-market-perform-from-outperform-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":["rate"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/innate-pharma-downgraded-to-market-perform-from-outperform-at-leerink-thefly?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IPHYF"],"gpt_icon":0},{"id":"2568460214","title":"Innate Pharma Reports H1 2025 Progress and Strategic Focus","url":"https://stock-news.laohu8.com/highlight/detail?id=2568460214","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568460214?lang=en_us&edition=fundamental","pubTime":"2025-09-17 18:58","pubTimestamp":1758106718,"startTime":"0","endTime":"0","summary":"An announcement from Innate Pharma SA ( ($FR:IPH) ) is now available. Innate Pharma SA reported its first half 2025 business update and financial r...","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/innate-pharma-reports-h1-2025-progress-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/innate-pharma-reports-h1-2025-progress-and-strategic-focus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IPHYF","PRGS","LU2065732104.USD","BK4097"],"gpt_icon":0},{"id":"2568452484","title":"Innate Pharma H1 EPS $(0.28) Up From $(0.34) YoY, Sales $5.51M Down From $13.35M YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2568452484","media":"Benzinga","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568452484?lang=en_us&edition=fundamental","pubTime":"2025-09-17 13:50","pubTimestamp":1758088237,"startTime":"0","endTime":"0","summary":"Innate Pharma (NASDAQ:IPHA) reported quarterly losses of $(0.28) per share. This is a 16.76 percent increase over losses of $(0.34) per share from the same period last year.  The company reported $5.51 million in sales","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/25/09/47707934/innate-pharma-h1-eps-0-28-up-from-0-34-yoy-sales-5-51m-down-from-13-35m-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IPHYF"],"gpt_icon":0}],"pageSize":20,"totalPage":2,"pageCount":1,"totalSize":24,"code":"91000000","status":"200"}]}}